Ocular Therapeutix™ to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference
December 05 2017 - 8:00AM
Business Wire
Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical
company focused on the development, manufacturing and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that management will be
hosting investor meetings at the Guggenheim Securities
5th Annual Boston Healthcare Conference on Wednesday, December
13, 2017 at The InterContinental Boston Hotel in Boston,
Massachusetts.
Investors attending the conference who are interested in meeting
with Ocular Therapeutix management should contact their Guggenheim
Securities representative.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused
on the development, manufacturing and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary hydrogel-based formulation technology. Ocular
Therapeutix’s lead product candidate, DEXTENZA™ (dexamethasone
insert) 0.4 mg for intracanalicular use, has completed Phase 3
clinical development for the treatment of ocular pain and
inflammation following ophthalmic surgery. OTX-TP (travoprost
insert) is in Phase 3 clinical development for the reduction of
intraocular pressure in patients with glaucoma and ocular
hypertension. The Company’s earlier stage assets include OTX-TIC, a
sustained release travoprost intracameral injection for the
reduction in intraocular pressure in patients with glaucoma and
ocular hypertension, as well as sustained release intravitreal
injections for the treatment of retinal diseases. These injections
include the development of OTX-TKI, a tyrosine kinase inhibitor
(TKI), and, in collaboration with Regeneron, an extended release
protein-based anti-vascular endothelial growth factor (VEGF) trap.
Ocular Therapeutix's first product, ReSure® Sealant, is
FDA-approved to seal corneal incisions following cataract
surgery.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171205005272/en/
InvestorsOcular TherapeutixDonald NotmanChief Financial
Officerdnotman@ocutx.comorWestwicke PartnersChris Brinzey,
339-970-2843chris.brinzey@westwicke.comorMediaOcular
TherapeutixScott CorningVice President of Marketing &
Commercial Operationsscorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Oct 2023 to Oct 2024